Rhythm Pharmaceuticals RYTM 深 滬
等待開盤 09-02 09:30:00 美东时间
103.15
-1.080
-1.04%
華盛通- 最 高104.62
- 今 開104.07
- 成交量 40.26万股
- 最 低 101.76
- 昨 收 104.23
- 總市值 65.63亿
- 52周最高 104.93
- 市盈率 靜 --
- 換手率 0.63%
- 52周最低 45.905
- 委 比 0.50%
- 總股本 6362.15万
- 歷史最高 104.93
- 量 比 0.71
- 振 幅 2.74%
- 歷史最低 3.04
- 每 手 1
- 風險率 13.83%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Agrify Corporation to Change Its Name to RYTHM, Inc. Following Brand Portfolio Acquisition
Agrify Corporation acquired the brand portfolio from Green Thumb Industries for $50 million via a convertible note, including RYTHM, Dogwalkers, and Beboe. They also entered a licensing agreement. Agrify will rebrand as RYTHM Inc and trade under "RYM" on Nasdaq from Sept. 2, 2025. The acquisition aims to position the company for growth in licensing revenue and THC product sales. The transaction results in ~2.0 million outstanding shares, 7.6 mill...
08-27 20:20
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
Dr. David Meeker, CEO of Rhythm Pharmaceuticals, will participate in fireside chats at the Wells Fargo Healthcare Conference on September 3, 2025, and the Morgan Stanley Global Healthcare Conference on September 9, 2025. Rhythm is a biopharmaceutical company focused on rare neuroendocrine diseases, with IMCIVREE® (setmelanotide) approved for obesity treatment in patients with BBS or specific genetic deficiencies. The drug is available in the U.S....
08-27 20:01
Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals announced the U.S. FDA has accepted its supplemental New Drug Application (sNDA) for setmelanotide to treat acquired hypothalamic obesity, granting Priority Review with a PDUFA goal date of December 20, 2025. The European Medicines Agency (EMA) also validated the Type II variation submission for the same indication. The company will host a commercial readiness event for investors and analysts on September 24, 2025, in Bosto...
08-20 20:01
New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data
Eli Lilly and Novo Nordisk are expected to price their new obesity pills in line with existing injections, as analysts cite affordability, supply capacity, and growing demand in the U.S. market.
08-20 02:29
93亿！礼来押注AI+蛋白质动力学Biotech
（来源：动脉新医药） 8月14日，Superluminal Medicines宣布与礼来合作，利用其专有平台发现和优化与心脏代谢疾病和肥胖相关的未公开GPCR靶...
08-15 17:54
美股大行评级 | Rivian遭多家大行下调目标价；巴克莱上调超微公司目标价从130美元升至200美元
今日重点评级关注：韦德布什：维持Gossamer Bio"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持EyePoint Pharmaceuticals"买入"评级，目标价从22美元升至23美元
08-07 09:46
12 Analysts Have This To Say About Rhythm Pharmaceuticals
Providing a diverse range of perspectives from bullish to bearish, 12 analysts ...
08-07 05:04
Guggenheim Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $120
Guggenheim analyst Seamus Fernandez maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $119 to $120.
08-06 22:56
Rhythm Pharmaceuticals Q2 EPS $(0.75) Misses $(0.64) Estimate, Sales $48.50M Beat $43.72M Estimate
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.64) by 16.82 percent. This is a 36.36 percent decrease over losses of $(0.55) per
08-05 19:03
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
